Found 157 clinical trials
Ovarian, Fallopian Tube or Peritoneal Cancer
Ovarian, Fallopian Tube or Peritoneal Cancer
- 675 views
- 08 Nov, 2020
- 1 location
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
- 532 views
- 08 Nov, 2020
- 1 location
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- 658 views
- 08 Nov, 2020
- 5 locations
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). (DUO-O)
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
- 119 views
- 24 Oct, 2022
- 20 locations
MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a)
This trial is a multicenter, prospective, phase II single arm, open-label trial in which patients with newly diagnosed advanced epithelial ovarian, primitive peritoneal, and fallopian tube cancer BRCA wild type, in partial or complete response to first line platinum-based chemotherapy, receive Olaparib maintenance therapy (300 mg, tablets formulation twice daily).
- 0 views
- 10 Mar, 2022
- 1 location
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer
ovarian, fallopian tube or primary peritoneal cancer. - The tolerability of the combination at the MTD of EGEN-001 assessed in combination with PLD. - The
- 233 views
- 08 Nov, 2020
- 1 location
Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE)
participants with high-grade serous ovarian cancer (HGSOC, including fallopian tube and primary peritoneal cancer). This study has an umbrella design. The trial consists of dose escalation (DES) and expansion
- 0 views
- 07 Oct, 2022
- 12 locations
NUVOLA TRIAL Open-label Multicentre Study (NUVOLA)
peritoneal tumour load. Nonetheless, BRCAmut women additionally show a higher benefit of platinum-based neoadjuvant chemotherapy (NACT) plus interval debulking surgery compared with BRCAwt women in
- 0 views
- 26 Feb, 2022
- 1 location
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
This study will evaluate the effectiveness and safety of intravenous injection of RC48-ADC in the treatment of HER2 expression (HER2 positive and HER2 low expression) gynecological malignancies.
- 1 views
- 21 Mar, 2022
- 1 location